NNC2215
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers. NNC2215 can sense the glucose concentration presence in blood, through incorporation of a glucose binding molecule developed in the University of Bristol. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. In addition, it can effectively cover the risk of fluctuations of blood sugar levels. The study was published on scientific journal Nature on October 16, 2024. This study demonstrated the ability of protein engineering in future medicine and a major advancement in treatment capabilities.
NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers. NNC2215 can sense the glucose concentration presence in blood, through incorporation of a glucose binding molecule developed in the University of Bristol. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. In addition, it can effectively cover the risk of fluctuations of blood sugar levels. The study was published on scientific journal Nature on October 16, 2024. This study demonstrated the ability of protein engineering in future medicine and a major advancement in treatment capabilities.
See also
Diabetes Hyperglycemia Hypoglycemia
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1336140168 under CC BY-SA 4.0; modifications have been made.
References
1 claim could not be tied to a specific sentence and is listed in the table below instead.